202. Dylan Beynon, Founder & CEO of Mindbloom

Today, I’m joined by Dylan Beynon, founder & CEO of
Mindbloom, a psychedelics-assisted therapy platform.


After discovering the transformative potential of psychedelics,
Dylan Beynon founded Mindbloom to empower individuals to improve
their mental and emotional well-being through guided psychedelic
experiences, meditation, and coaching. Facilitated by trained
guides, the telemedicine platform employs clinician-prescribed
ketamine therapy to alleviate symptoms of depression, anxiety,
and PTSD.


In this episode, we talk about barriers to care during a national
mental health crisis. Plus, we explore navigating at-home
psychedelic experiences and Mindbloom’s plans should psilocybin
(aka “magic mushrooms”) become legal.


In this episode, you’ll learn:


• How ketamine therapy radically changed the lives of Dylan and
his family
• The difficulties of working in heavily regulated
industries
• Mindbloom’s therapy process and how they team up with mental
healthcare providers


Subscribe to the podcast insider.fitt.co/podcast
Subscribe to our newsletter insider.fitt.co/subscribe
Follow us on LinkedIn linkedin.com/company/fittinsider


Mindbloom’s Website: https://www.mindbloom.com/
Mindbloom’s socials: @mindbloom
Dylan’s LinkedIn: https://www.linkedin.com/in/dylanbeynon/


-


The Fitt Insider podcast is brought to you by Jack Taylor, our
exclusive PR partner. More than just PR, they’re creative
storytellers and brand builders who actually understand the
health and wellness industry. Learn more and get in touch at
https://fitt.co/jacktaylor



Chapters:
(00:00) Introduction
(01:34) About Mindbloom 
(03:44) Ketamine therapy 
(07:57) The mental health crisis
(12:29) Treating mental illness with SSRIs vs. ketamine
therapy
(19:39) Healthcare professionals utilizing ketamine therapy at
their practice
(22:54) Regulatory considerations and challenges
(28:04) Patient testimonials are the best marketing
(30:51) Future roadmap
(33:58) Improving treatments for mental illnesses
(37:32) Views on legalization of psychedelic drugs
(41:48) Key Takeaway
(43:09) Conclusion